Biotage Makes a Change in Top Management after Business Area President resigns

UPPSALA, SWEDEN. The life science company Biotage, listed on the O-list of the Stockholm stock exchange, makes a change in its top management. David Patteson, President of the business area Discovery Chemistry has decided to seek new challenges elsewhere. He will leave the company on 1 April 2006. David Patteson has been with Biotage for seven years during which time he has very successfully built up the Global operations. In the last years he also led the integration of the acquired companies and the cost reductions that followed. Today, Biotage is the world leading supplier in instruments, reagents and services for the Medicinal Chemists. The forthcoming CEO of Biotage, Torben Jörgensen, will take over Mr Patteson’s responsibilities with immediate effect and work alongside him until 1 April. Discovery Chemistry, which represents about 85 percent of Biotage’s annual turnover, supplies products and services for three prominent market segments, Medicinal Chemistry, Analytical Chemistry and Process Development. Primary products include microwave synthesis, resins and solid phase extraction (SPE), flash purification cartridges and systems, and reaction screening instruments, which target chemists in research organizations worldwide. For more information, please contact: Mikael Widell, +46 (0)703 11 99 60

About Us

Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by public authorities, academic institutions, contract research and contract manufacturing organizations and in the pharmaceutical and food industries, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan and South Korea. Biotage has approx. 330 employees and had sales of 667 MSEK in 2016. Biotage is listed on Nasdaq Stockholm. Website:


Documents & Links